For
UK
audiences
The professional's guide to product selection
The professional's guide to product selection
• Adults: 2–3 drops into each nostril twice daily.
For non-infected inflammatory conditions of nose.
Nose drop solutions
Betnesol 0.1%, 1 mg/ml, 10 ml
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis of mild to moderate asthma by inhalation of powder
• Child 6 months–11 years: 200–400 micrograms once daily, dose to be given in the evening.
• Over 12 years: 200–400 micrograms once daily (max. per dose 800 micrograms), dose to be given in the evening.
Prophylaxis of asthma by inhalation of powder
• Child 6 months–11 years: 100–400 micrograms twice daily, dose to be adjusted as necessary.
• Over 12 years: 100–800 micrograms twice daily, dose to be adjusted as necessary.
Prophylaxis as treatment of allergic and vasomotor rhinitis by intranasal administration
• Child 6-17 years: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
• Adult: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
For allergic rhinitis
• Over 12 years: one spray twice daily, dose to be administered into each nostril.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis of mild to moderate asthma by inhalation of powder
• Child 6 months–11 years: 200–400 micrograms once daily, dose to be given in the evening.
• Over 12 years: 200–400 micrograms once daily (max. per dose 800 micrograms), dose to be given in the evening.
Prophylaxis of asthma by inhalation of powder
• Child 6 months–11 years: 100–400 micrograms twice daily, dose to be adjusted as necessary.
• Over 12 years: 100–800 micrograms twice daily, dose to be adjusted as necessary.
Prophylaxis as treatment of allergic and vasomotor rhinitis by intranasal administration
• Child 6-17 years: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
• Adult: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
For allergic rhinitis
• Over 12 years: one spray twice daily, dose to be administered into each nostril.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.